Drug Profile
Ubamatamab - Regeneron Pharmaceuticals
Alternative Names: Anti MUC16-CD3 antibody; Anti-MUC16/CD3-BiTE-antibody-REGN4018; antiMUC16-antiCD3-monoclonal-antibodies; Bispecific-T-cell-engager-antibody-REGN-4018; BiTE-antibody-REGN-4018; MUC16xCD3-bispecific-monoclonal-antibodies; REGN4018Latest Information Update: 10 Dec 2023
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ovarian cancer
- Phase I/II Fallopian tube cancer; Peritoneal cancer
Most Recent Events
- 05 Dec 2023 Phase-I/II clinical trials in Fallopian tube cancer (Combination therapy, Recurrent, Second-line therapy or greater, Late-stage disease) in France, Israel, Italy, South Korea, Netherlands (IV) (NCT03564340)
- 05 Dec 2023 Phase-I/II clinical trials in Fallopian tube cancer (Monotherapy, Recurrent, Late-stage disease, Second-line therapy or greater) in France, Israel, Italy, South Korea, Netherlands (IV) (NCT03564340)
- 05 Dec 2023 Phase-I/II clinical trials in Ovarian cancer (Combination therapy, Second-line therapy or greater, Recurrent, Late-stage disease) in France, Israel, Italy, South Korea, Netherlands (IV) (NCT03564340)